Element Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Element Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,841	Closed	-$271K	–	274
2019 Q1	$271K	Buy	+3,841	New	+$226K	0.01%	628
2018 Q3	–	Sell	-3,585	Closed	-$239K	–	887
2018 Q2	$239K	Buy	+3,585	New	+$224K	0.01%	646

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Element Capital Management's ANIP Position: Q2 2019 in Review

Element Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2019, closing a stake of 3,841 shares — an estimated $271K sold.

Element Capital Management first reported a position in ANIP in Q2 2018 and held it in 2 quarters. The position peaked at $271K in Q1 2019. 196 funds tracked by Wall St. Rank hold ANIP as of Q2 2019.

Element Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Element Capital Management sold 3,841 ANI Pharmaceuticals shares in Q2 2019, an estimated $271K.
Element Capital Management first reported a position in ANI Pharmaceuticals in Q2 2018 and held it in 2 quarters.
Element Capital Management's ANI Pharmaceuticals position peaked at $271K in Q1 2019.
196 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.